Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Block Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 3.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Block Inc for 78 Days on average.
| HALO | XYZ | |
|---|---|---|
Market Cap | $12.58B | $45.20B |
Volume | 2,179,278 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $115.22 | $84.85 |
52-Week Low | $61.63 | $49.04 |
Typical Hold Time | 1 Days | 78 Days |
Enterprise Value | $14.49B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Block (XYZ) trades at $77.24, up 1.54% today, with strong analyst support (77% buy ratings) and a $97.47 consensus price target suggesting 26% upside. Recent quarters show earnings momentum with Q1 and Q2 2026 beats, though Q3 2026 results are pending. Revenue growth has been steady, reaching $24.19B in 2025, but net margins remain thin at 1.43%. Technical indicators are bearish overall, with the stock testing resistance near $77.
The stock offers growth potential from expanding Square and Cash App ecosystems and new banking initiatives, but faces risks from high P/E valuation (134.34), competitive pressures, and insider selling. Positive earnings surprises and institutional accumulation provide support, though profitability consistency and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
